Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 
 

Asco 2015 - Welcoming Collaboration, Driving Innovation

“We are eager to share the latest early data for avelumab at ASCO,” said Belén Garijo, Member of our executive Board and CEO Healthcare, “this is the first time we will be presenting data on avelumab as an alliance. And we are making good progress with our Evofosfamide drug candidate for the possible treatment of pancreatic cancer as well as soft tissue sarcoma.”

 

Asco 2015 (May 29 – June 2, Chicago, USA)

At this year’s Asco annual meeting we for the first time hosted a media briefing together with Pfizer, our partner in the field of immuno-onncology. This event took place May 31st. Here we provide latest information about our drug candidates avelumab, evofosfamide and disease areas we are targeting.

Background information

Additional Information

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 
Merck KGaA, Darmstadt, Germany on Facebook
Merck KGaA, Darmstadt, Germany on LinkedIn
Twitter